Cancer Pain
Conditions
Keywords
reduction
Brief summary
The investigators propose to conduct a study in medically refractory cancer pain patients utilizing radiosurgery to ablate the pituitary hypophysis, as well as neuromodulate the centromedian and parafascicular complexes within the thalami - the so-called triple target. This involves treating the pituitary hypophysis and thalamus to a dose of 90 Gy. These patients will have previously failed to achieve adequate pain control with opioid pain regimens and interventional approaches. The trial will involve a multidisciplinary approach involving radiation oncology, neurosurgery, palliative care, and medical oncology colleagues across UCLA.
Detailed description
Refractory pain is one of the most debilitating challenges in oncology patients, particularly at the end of life. Over 60% of cancer patients experience pain, with 30% of these patients becoming refractory to opioid pain medication. Interventional techniques such as nerve blocks and pain pumps only transiently relieve pain and are often not viable for advanced cancer patients. In patients with diffuse metastatic disease with less than 3-6 months survival, there is a pressing need for a rapid and thorough relief of pain sensation. Recently, using highly focused radiation delivered to very unique targets in the brain, patients can have marked reduction in perceived pain. There are centers in the brain dubbed as gateways of pain, including the pituitary hypophysis1 and the centromedian and parafascicular complexes2, with some preliminary data also involving the anterior cingulum. Ablation or neuromodulation of these targets with focused high doses of radiation have been shown in small series to provide pain relief in \ 3.5 days with a 50% reduction of perceived pain. The investigators propose to conduct a study in medically refractory cancer pain patients utilizing radiosurgery to ablate the pituitary hypophysis, as well as neuromodulate the centromedian and parafascicular complexes within the thalami - the so-called “triple target.†3 This involves treating the pituitary hypophysis and thalamus to a dose of 90 Gy. These patients will have previously failed to achieve adequate pain control with opioid pain regimens and interventional approaches. This trial will involve a multidisciplinary approach involving radiation oncology, neurosurgery, palliative care, and medical oncology colleagues across UCLA.
Interventions
RADIATIONRadiosurgery
intracranial functional stereotactic radiosurgery (FnSRS) to the triple target: centromedian-parafasciular complex bilaterally, and the hypophysis
Sponsors
Jonsson Comprehensive Cancer Center
Brainlab AG
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female ≥ 18 years of age on day of SRS treatment. 2. Documentation of insufficiently controlled mixed, complex cancer pain based on Brief Pain Inventory (BPI) \>8/10 despite optimization of opioid regimen 3. Not eligible for or willing to undergo further pain-relieving interventions 4. Written informed consent (and assent when applicable) obtained from patient or patient's legal representative and ability for patient to comply with the study requirements and agree to undergo the study's SRS treatment plan.
Exclusion criteria
1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. 2. Claustrophobia or inability to life flat 3. Inability to undergo routine imaging studies 4. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 5. Current history of intracranial malignancy or brain metastasis 6. Any prior intracranial irradiation 7. Previous history of craniotomy, deep brain stimulation (DBS) or laser interstitial themal therapy (LITT). 8. Presence of intracranial hardware such as leads for DBS or any other material that may interfere with safe treatment. 9. Any comorbidity or condition which would limit full compliance with the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain Inventory | - Baseline: Daily measurements on three separate days prior to treatment (Day -7 +/- 3 days, Day -3 +/- 1 day, Day -2 +/- 1 day)- Post-baseline: Days +1, 2, 3, 4, 7, 14, 21, 28 | For each patient, investigator will measure the Brief Pain Inventory (BPI) (score range: 0-10) at the following days. Higher score indicates greater pain perception. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Opioid Usage Quantification | o Pre-study (screening visit) and Baseline (Day-7, Day-3, & Day-2)o Days +1, 2, 3, 4, 7, 14, 21, 28 | (1) To describe opioid daily consumption pre- and post-treatment |
| functional stereotactic radiosurgery (FnSRS) treatment side effects | 28 days post treatment | To characterize the side effect profile of FnSRS for treatment of intracranial triple targets |
| Pain anxiety symptom scale (PASS-20) | Baseline visit (Day -7) Day +28 after treatment. | To evaluate the changes in neuropsychiatric metrics, quality of life and executive function after FnSRS for modulation of intracranial triple targets. Assesses fear, avoidance, and anxiety related to pain. (0-5, 0=Never, 5=Always); higher scores indicate a worse assessment. |
| 17-item Hamilton Depression Rating Scale: | Baseline visit (Day -7) Day +28 after treatment. | Evaluates the severity of depressive symptoms. (0-4, 0=Absent, 4=Very Severe); higher scores indicate a worse assessment. |
| Hamilton Anxiety Rating Scale | Baseline visit (Day -7) Day +28 after treatment. | Measures the severity of anxiety symptoms. (0-4, 0=Not Present, 4=Very Severe); higher scores indicate a worse assessment. |
| Pittsburgh Sleep Quality Index | Baseline visit (Day -7) Day +28 after treatment. | Assesses sleep quality and disturbances over a one-month period. (0-3, 0=Not During the past month, 3=Three or more times a week); higher scores indicate a worse assessment. |
| Social disability screening schedule/WHO disability assessment schedule | Baseline visit (Day -7) Day +28 after treatment. | Measures social functioning and disability in various life domains. (0-4, 0=None, 4=Extreme or Cannot Do); higher scores indicate a worse assessment. |
| Activity of Daily Living Scale | Baseline visit (Day -7) Day +28 after treatment. | Evaluates the ability to perform basic self-care and everyday activities. (0-3 or NA, 0=Appropriate, 3=Cannot do by self alone at all; Not Applicable); higher scores indicate a worse assessment. |
| 36-item Short Form-Health Survey/RAND-36 | Baseline visit (Day -7) Day +28 after treatment. | Assesses health-related quality of life across multiple dimensions, including physical, mental, and social well-being. (0=2, 0=No, not limited at all; 2=Yes, Limited a lot); higher scores indicate a worse assessment. |
Countries
United States
Contacts
CONTACTWilliam Delery
CONTACTChristy Palodichuk
Outcome results
None listed